Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Maxwell

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Cancer Discovery|September 23, 2016
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast CancerJoseph Vijai, Sabine Topka, Danylo Villano, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
JCO Precision Oncology|September 21, 2020
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary CancersKara N Maxwell, Brandon M Wenz, Abha Kulkarni, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2024
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathiesMelissa R Perrino, Anirban Das, Sarah R Scollon, et al.
Nature Communications|November 21, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Leukemia|July 9, 2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress responseSarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier, et al.
BMC Public Health|September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testingAmy E Leader, Timothy R Rebbeck, William K Oh, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Cancer Discovery|September 23, 2016
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast CancerJoseph Vijai, Sabine Topka, Danylo Villano, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
JCO Precision Oncology|September 21, 2020
Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary CancersKara N Maxwell, Brandon M Wenz, Abha Kulkarni, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2024
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathiesMelissa R Perrino, Anirban Das, Sarah R Scollon, et al.
Nature Communications|November 21, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Leukemia|July 9, 2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress responseSarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier, et al.
BMC Public Health|September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testingAmy E Leader, Timothy R Rebbeck, William K Oh, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Pageof 20